MIRM insider ownership: who sold, why, and what they still hold

What stands out

Jolanda Howe sold $4.0M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Aug 18, 2026

A share of stake is shown for 0 of the 7 officers and directors who sold. 14 are left out

Left out: Christopher Peetz, Michael Grey, Eric Bjerkholt, Peter Radovich, Laura Brege, Laurent Fischer, Patrick Heron, Lon Cardon, Timothy Walbert, Joanne Quan, William Fairey, Jolanda Howe, Robert Myers and Saira Ramasastry (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Christopher Peetz

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$16.3M63% planned, 37% to cover taxes

Michael Grey

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$11.1MDisclosed plan

Jolanda Howe

SVP, Global Controller

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.6M15% planned, 13% to cover taxes 72% no plan disclosed

Eric Bjerkholt

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$3.6M47% planned, 53% to cover taxes

Peter Radovich

President and COO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.3MTo cover taxes

All 7 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Sep 14, 2026Eric Bjerkholt sold 9.9K shares ($978K) to cover taxes on vesting stock.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Eric Bjerkholt Chief Financial Officer	9,943	$98.37	n/a	n/a	Sep 14, 2026	Sep 15, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

Patrick Heron reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Mirum Pharmaceuticals, Inc. CEO selling stock?

Yes. Christopher Peetz sold 164K shares ($16.3M) in the past 12 months, 63% of it under a trading plan disclosed in the filings.

Why are Mirum Pharmaceuticals, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 61% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 29% were to cover taxes and 9% had no disclosed plan. A trading plan schedules sales in advance.

Are any Mirum Pharmaceuticals, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold7 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Christopher Peetz Chief Executive Officer, Director	$16.3M 164K shares	Not confirmed share of stake is being verified. Why	63% under a disclosed plan, 37% to cover taxes
Michael Grey Director	$11.1M 150K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Jolanda Howe SVP, Global Controller	$5.6M 55K shares	Not confirmed share of stake is being verified. Why	15% under a disclosed plan, 13% to cover taxes 72% no plan disclosed
Eric Bjerkholt Chief Financial Officer	$3.6M 36K shares	Not confirmed share of stake is being verified. Why	47% under a disclosed plan, 53% to cover taxes
Peter Radovich President and COO	$2.3M 25K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Saira Ramasastry Director	$1.9M 21K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Joanne Quan Chief Medical Officer	$1.5M 16K shares	Not confirmed share of stake is being verified. Why	To cover taxes

Board members representing outside shareholders, reported separately: Patrick Heron. Details

The full ownership picture0 of 14 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Christopher Peetz

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Christopher Peetz are complete.

Chief Executive Officer, Director

n/a

−164K

n/a

Vesting, gifts, unvested awards and holding lines for Christopher Peetz

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Peetz are complete; balances and unit counts will be added when the check is finished.

−21Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
278,487	$2.94	Mar 11, 2029	$26.6M
150,000	$26.49	Jan 22, 2034	$10.8M
153,550	$47.98	Jan 20, 2035	$7.7M
58,487	$2.94	Mar 11, 2029	$5.6M
150,867	$19.24	Jan 9, 2030	$11.9M
67,000	$100.85	Jan 27, 2036	$0
169,695	$19.19	Jan 6, 2031	$13.4M
233,108	$15.87	Jan 5, 2032	$19.2M

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Michael Grey

Director

n/a

−150K

n/a

Vesting, gifts, unvested awards and holding lines for Michael Grey

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Grey are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
181,176	$2.94	Mar 11, 2029	$17.3M
8,779	$26.30	Jun 4, 2034	$633K
6,268	$44.00	May 28, 2035	$341K
3,772	$101.00	Jun 14, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Eric Bjerkholt

Chief Financial Officer

n/a

−36K

n/a

Vesting, gifts, unvested awards and holding lines for Eric Bjerkholt

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eric Bjerkholt are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Some sales match sales reported by Joanne Quan exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
32,000	$26.49	Jan 22, 2034	$2.3M
40,000	$47.98	Jan 20, 2035	$2.0M
26,653	$26.49	Jan 22, 2034	$1.9M
18,140	$100.85	Jan 27, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Peter Radovich

President and COO

n/a

−25K

n/a

Vesting, gifts, unvested awards and holding lines for Peter Radovich

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Peter Radovich are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
48,012	$19.19	Jan 6, 2031	$3.8M
54,088	$15.87	Jan 5, 2032	$4.5M
70,000	$26.49	Jan 22, 2034	$5.0M
50,000	$47.98	Jan 20, 2035	$2.5M
25,120	$100.85	Jan 27, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Laura Brege

Director

n/a

Vesting, gifts, unvested awards and holding lines for Laura Brege

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Laura Brege are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,779	$26.30	Jun 4, 2034	$633K
6,268	$44.00	May 28, 2035	$341K
3,772	$101.00	Jun 14, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Laurent Fischer

Director

n/a

Vesting, gifts, unvested awards and holding lines for Laurent Fischer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Laurent Fischer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,779	$26.30	Jun 4, 2034	$633K
6,268	$44.00	May 28, 2035	$341K
3,772	$101.00	Jun 14, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Patrick Heron

Director

n/a

Vesting, gifts, unvested awards and holding lines for Patrick Heron

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Patrick Heron are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,779	$26.30	Jun 4, 2034	$633K
6,268	$44.00	May 28, 2035	$341K
3,772	$101.00	Jun 14, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Lon Cardon

Director

n/a

Vesting, gifts, unvested awards and holding lines for Lon Cardon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lon Cardon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,779	$26.30	Jun 4, 2034	$633K
6,268	$44.00	May 28, 2035	$341K
3,772	$101.00	Jun 14, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Timothy Walbert

Director

n/a

Vesting, gifts, unvested awards and holding lines for Timothy Walbert

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Timothy Walbert are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,779	$26.30	Jun 4, 2034	$633K
6,268	$44.00	May 28, 2035	$341K
3,772	$101.00	Jun 14, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Joanne Quan

Chief Medical Officer

n/a

−16K

n/a

Vesting, gifts, unvested awards and holding lines for Joanne Quan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joanne Quan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Some sales match sales reported by Eric Bjerkholt exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
75,000	$26.72	Jan 15, 2034	$5.4M
40,000	$47.98	Jan 20, 2035	$2.0M
18,140	$100.85	Jan 27, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

William Fairey

Director

n/a

Vesting, gifts, unvested awards and holding lines for William Fairey

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for William Fairey are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,779	$26.30	Jun 4, 2034	$633K
6,268	$44.00	May 28, 2035	$341K
3,772	$101.00	Jun 14, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Jolanda Howe

SVP, Global Controller

n/a

−55K

n/a

Vesting, gifts, unvested awards and holding lines for Jolanda Howe

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jolanda Howe are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
18,000	$26.49	Jan 22, 2034	$1.3M
18,500	$47.98	Jan 20, 2035	$932K
7,680	$100.85	Jan 27, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Robert Myers

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Robert Myers

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Myers are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Saira Ramasastry

Director

n/a

−21K

n/a

Vesting, gifts, unvested awards and holding lines for Saira Ramasastry

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Saira Ramasastry are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,779	$26.30	Jun 4, 2034	$633K
6,268	$44.00	May 28, 2035	$341K
3,772	$101.00	Jun 14, 2036	$0

Estimate: options held × ($98.37 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Holdings and share of stake for Mirum Pharmaceuticals, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$42.2M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $42.2M across 466,676 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $25.8M · 61%

39%

The lighter segment is sales with no plan disclosed in the filing ($16.4M), including tax-related sales outside a plan.

No plan disclosed · $4.0M

Sales with no 10b5-1 plan and no tax reference in the filing. $4.0M of it is Jolanda Howe. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Jolanda Howe, Aug 18, 2026

Taxes

$12.4M of sales (29.4%) cite tax obligations in their footnotes. Example: Eric Bjerkholt, Sep 14, 2026

Charitable gifts · 21K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Christopher Peetz Chief Executive Officer, Director	164K	$16.3M	63%	39%	Jan 22, 2026 to Sep 1, 2026
Michael Grey Director	150K	$11.1M	100%	26%	Nov 21, 2025 to Dec 19, 2025
Jolanda Howe SVP, Global Controller	55K	$5.6M	15%	13%	Jan 22, 2026 to Sep 2, 2026
Eric Bjerkholt Chief Financial Officer	36K	$3.6M	47%	8%	Jan 22, 2026 to Sep 14, 2026
Peter Radovich President and COO	25K	$2.3M	0%	5%	Jan 22, 2026 to Mar 16, 2026
Saira Ramasastry Director	21K	$1.9M	100%	5%	Dec 18, 2025 to Jun 1, 2026
Joanne Quan Chief Medical Officer	16K	$1.5M	0%	3%	Jan 20, 2026 to Mar 16, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$3.5M	$3.5M	$0	$0
Dec 2025	$8.1M	$8.1M	$0	$0
Jan 2026	$3.2M	$182K	$3.0M	$0
Feb 2026	$1.5M	$204K	$1.3M	$0
Mar 2026	$7.2M	$182K	$7.1M	$0
Apr 2026	$194K	$194K	$0	$0
May 2026	$219K	$219K	$0	$0
Jun 2026	$4.0M	$4.0M	$0	$0
Jul 2026	$3.4M	$3.4M	$0	$0
Aug 2026	$6.8M	$2.8M	$0	$4.0M
Sep 2026	$4.0M	$3.0M	$978K	$0
Oct 2026	$0	$0	$0	$0

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 13, 2025	Sold	Held Oct 13, 2026	Still held
Patrick Heron ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Patrick Heron are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Patrick Heron Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Patrick Heron are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Is this normal? Selling year by year5 earlier years to compare with

More than usual: $42.2M sold, after almost none in the past 5 years. 7 insiders sold; the average is 5 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	467K	7	$42.2M
Oct 13, 2025 1 year earlier	347K	8	$16.6M
Oct 13, 2024 2 years earlier	63K	6	$1.9M
Oct 14, 2023 3 years earlier	66K	6	$1.8M
Oct 14, 2022 4 years earlier	0	0	$0
Oct 14, 2021 5 years earlier	10K	6	$198K

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty14 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Mirum Pharmaceuticals, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology351 filings on record, 65 filed in the 12-month period, and how we read them

All 351 Forms 3, 4 and 5 on record for Mirum Pharmaceuticals, Inc. (SEC CIK 1759425), filed from Jul 17, 2019 to Oct 6, 2026; 65 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (25)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Pamela Vig	Jun 25, 2024	102,406 shares, last reported balance as of Jun 24, 2024
Lara Longpre	Mar 18, 2024	104,407 shares, last reported balance as of Feb 2, 2024
New Enterprise Associates 16, L.P.	Jun 15, 2023	2,186,243 shares, last reported balance as of Jun 13, 2023
Forest Baskett	Jun 15, 2023	2,187,791 shares, last reported balance as of Jun 13, 2023
Ali Behbahani	Jun 15, 2023	2,186,378 shares, last reported balance as of Jun 13, 2023
Carmen Chang	Jun 15, 2023	2,186,378 shares, last reported balance as of Jun 13, 2023
Anthony Florence Jr.	Jun 15, 2023	2,197,975 shares, last reported balance as of Jun 13, 2023
Mohamad Makhzoumi	Jun 15, 2023	2,197,744 shares, last reported balance as of Jun 13, 2023
Scott Sandell	Jun 15, 2023	2,199,372 shares, last reported balance as of Jun 13, 2023
Paul Walker	Jun 15, 2023	2,186,357 shares, last reported balance as of Jun 13, 2023
Niall O'Donnell	Nov 15, 2022	No balance on record
Niall O'Donnell	Nov 15, 2022	1,621,118 shares, last reported balance as of Nov 15, 2022
Ian Clements	Nov 14, 2022	30,011 shares, last reported balance as of Nov 10, 2022
James Flynn	Jun 8, 2022	3,244,434 shares, last reported balance as of Jun 6, 2022
Edward Mathers	Jun 6, 2022	No balance on record
Carol Brosgart	Jun 6, 2022	No balance on record
Edwin Tucker	Nov 15, 2021	45,838 shares, last reported balance as of Nov 10, 2021
Peter Barris	Jul 24, 2019	4,186,243 shares, last reported balance as of Jul 22, 2019
Joshua Makower	Jul 24, 2019	4,186,243 shares, last reported balance as of Jul 22, 2019
Peter Sonsini	Jul 24, 2019	4,186,243 shares, last reported balance as of Jul 22, 2019
David Mott	Jul 24, 2019	4,186,243 shares, last reported balance as of Jul 22, 2019
Frazier Life Sciences IX, L.P.	Jul 24, 2019	3,566,912 shares, last reported balance as of Jul 22, 2019
Novo Holdings A/S	Jul 23, 2019	2,445,147 shares, last reported balance as of Jul 22, 2019
TAKEDA PHARMACEUTICAL CO LTD	Jul 17, 2019	1,859,151 shares, last reported balance as of Jul 17, 2019
Tiba Aynechi		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Mirum Pharmaceuticals, Inc. insiders sold $42.2M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Mirum Pharmaceuticals, Inc. CEO selling stock?

Why are Mirum Pharmaceuticals, Inc. insiders selling?

Are any Mirum Pharmaceuticals, Inc. insiders buying?

The evidence

No plan disclosed · $4.0M

Taxes

Charitable gifts · 21K shares

Sales by month